| Autor: |
Latagliata, Roberto, Cambò, Benedetta, Piccioni, Anna Lina, Federico, Vincenzo, Cristiano, Gianluca, Lugli, Elisabetta, Rizzo, Lorenzo, Santopietro, Michelina, Mazzone, Carla, Bonifacio, Massimiliano, Palmieri, Raffaele, Poloni, Antonella, Biagi, Annalisa, Binotto, Gianni, Delfina, Marzia, Annunziata, Mario, Molteni, Alfredo, Piedimonte, Monica, Carmosino, Ida, Di Veroli, Ambra, Niscola, Pasquale, Riva, Marta, Capodanno, Isabella, Curti, Antonio, Di Rienzo, Nicola, Fenu, Susanna, Crugnola, Monica |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p6497-6497, 1p |
| Abstrakt: |
BackgroundSurvival of high-risk Myelodysplastic Syndromes (MDS) treated with azacytidine during the dysplastic phase and then evolved in Acute Myeloid Leukemia (AML-MDS) is very poor. While the association of hypometilating agents (HMA) and venetoclax (VEN) is widely used in de novo AML not eligible for intensive chemotherapy, very few data are available in patients (pts) with AML-MDS. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
